Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 5/20 | 0.35 |
| ▸ | INSR | P06213 | 4/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448507 | 0.94 | EGFR (0.39) | EGFRERBB2FGFR1BRD4P2RX3 | |
| SCHEMBL3447997 | 0.93 | EGFR (0.41) | EGFRERBB2FGFR1BRD4P2RX3 | |
| SCHEMBL3448252 | 0.92 | CSNK2A1 (0.37) | EGFRMETINSRSYKCSNK2A1 | |
| SCHEMBL3448591 | 0.90 | EGFR (0.38) | EGFRERBB2FGFR1BRD4MET | |
| SCHEMBL3451838 | 0.88 | EGFR (0.38) | EGFRERBB2FGFR1BRD4P2RX3 | |
| SCHEMBL3448417 | 0.86 | RAF1 (0.36) | EGFRFGFR1SYKJAK2JAK3 | |
| SCHEMBL3448739 | 0.86 | MAPT (0.36) | EGFRFGFR1SYKCSNK2A1 | |
| SCHEMBL3448766 | 0.85 | EGFR (0.38) | EGFRERBB2FGFR1BRD4P2RX3 | |
| SCHEMBL3451841 | 0.85 | EGFR (0.40) | EGFRERBB2FGFR1BRD4P2RX3 | |
| SCHEMBL3449417 | 0.85 | SYK (0.38) | EGFRERBB2FGFR1SYKPAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | EGFR 2771/4885ERBB2 2537/4885FGFR1 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.